Skip to main content

Table 2 Expression of VIM (Z-score ≥ 1) according to the top mutations present in AML (N = 173 patients)

From: Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia

Genes Z-score (< 1) (n = 145) Z-score (≥ 1) (n = 28) p value
FLT3 (n, %) 41 (28.3%) 8 (28.6%) > 0.999
TP53 (n, %) 14 (9.66%) 0 (0.00%) 0.130
NPM1 (n, %) 35 (24.1%) 13 (46.4%) 0.021
NRAS (n, %) 10 (6.90%) 2 (7.14%) > 0.999
TET2 (n, %) 14 (9.66%) 1 (3.57%) 0.470
RUNX1 (n, %) 14 (9.66%) 1 (3.57%) 0.470
CEBPA (n, %) 12 (8.28%) 1 (3.57%) 0.696
WT1 (n, %) 10 (6.90%) 0 (0.00%) 0.369
DNMT3A (n, %) 34 (23.4%) 8 (28.6%) 0.631
IDH1 (n, %) 13 (8.97%) 3 (10.7%) 0.726
IDH2 (n, %) 13 (8.97%) 4 (14.3%) 0.484